Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141774

Published: 2020

Journal Articles

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Mareike Rasche, MD, Emma Steidel, Martin Zimmermann, Jean-Pierre Bourquin, MD PhD, Heidrun Boztug, Iveta Janotová, Edward A. Kolb, MD, Thomas Lehrnbecher, Nils Von Neuhoff, PhD, Naghmeh Niktoreh, Nora Muehlegger, Lucie Sramkova, MD, Jan Stary, MD PhD, Christiane Walter, MSc, Ursula Creutzig, MD PhD, Michael Dworzak, MD PhD, Dirk Reinhardt, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-139317

Published: 2020

Journal Articles

Treatment‐Related Acute Myeloid Leukemia in Children

Katharina Waack, Katharina Röllecke, PhD, Mareike Rasche, MD, Christiane Walter, MSc, Ursula Creutzig, MD PhD, Dirk Reinhardt, MD PhD

Blood (2019) 134 (Supplement_1): 1322.

https://doi.org/10.1182/blood-2019-131911

Published: 2019

Journal Articles

The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study

Blood (2016) 128 (22): 2896.

https://doi.org/10.1182/blood.V128.22.2896.2896

Published: 2016

Journal Articles

Gemtuzumab in Children with Relapsed and Refractory Acute Myeloid Leukemia Treated on Compassionate-Use Basis: A Report of the AML-BFM Study Group

Mareike Rasche, MD, Beate Lerius, Ursula Creutzig, MD PhD, Martin Zimmermann, PhD, C. Michel Zwaan, MD PhD, Dirk Reinhardt, MD PhD

Blood (2016) 128 (22): 1637.

https://doi.org/10.1182/blood.V128.22.1637.1637

Published: 2016

Journal Articles

Successes and Challenges of Pediatric AML: A Report on Survival, Salvage Therapy and Causes of Deaths in the AML-BFM Study Group from 1987 -2012

Mareike Rasche, MD, Martin Zimmermann, PhD, Lisa Kellerstrass, Ursula Creutzig, MD PhD, Jan-Henning Klusmann, MD, Dirk Reinhardt, MD PhD

Blood (2016) 128 (22): 450.

https://doi.org/10.1182/blood.V128.22.450.450

Published: 2016

Journal Articles

Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML

Blood (2014) 124 (21): 481.

https://doi.org/10.1182/blood.V124.21.481.481

Published: 2014

Journal Articles

Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG)

Blood (2014) 124 (21): 3670.

https://doi.org/10.1182/blood.V124.21.3670.3670

Published: 2014

Journal Articles

Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML.

Ursula Creutzig, MD, PhD, Martin Zimmermann, PhD, Michael Dworzak, Jean-Pierre Bourquin, MD, PhD, Christine von Neuhoff, MD, Annette Sander, MD, Jan Stary, Dirk Reinhardt, MD

Blood (2012) 120 (21): 2621.

https://doi.org/10.1182/blood.V120.21.2621.2621

Published: 2012

Journal Articles

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Zinia J. Kwidama, BSc, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Evelina S De Bont, MD, PhD, Sara Elitzur, MD, Carmelo Rizzari, MD, PhD, Valérie de Haas, MD, PhD, Martin Zimmermann, Jacqueline Cloos, PhD, Gertjan J.L. Kaspers, MD, PhD

Blood (2012) 120 (21): 2480.

https://doi.org/10.1182/blood.V120.21.2480.2480

Published: 2012

Journal Articles

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Monique L. Den Boer, PhD, Zinia J. Kwidama, BSc, Evelina S. De Bont, MD, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Valérie de Haas, MD, PhD, Yehuda Assaraf, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2012) 120 (21): 283.

https://doi.org/10.1182/blood.V120.21.283.283

Published: 2012

Journal Articles

Transient and Myeloid Leukemia in Children with Down Syndrome Mosaic

Alexandra Kolenova, MD, PhD, Katarina Reinhardt, PhD, Michaela Nathrath, MD, Claudia Rossig, MD, PhD, Arend von Stackelberg, MD, Christine von Neuhoff, MD, Annette Sander, MD, Peter Svec, MD, PhD, C. Michel Zwaan, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2011) 118 (21): 2539.

https://doi.org/10.1182/blood.V118.21.2539.2539

Published: 2011

Journal Articles

Glucocorticoid-Induced Proliferation and Differentiation of Untreated Pediatric AML Cells

Eric Haarman, MD, PhD, Jacqueline Cloos, PhD, Christian M. Zwaan, MD, PhD, Valerie de Haas, MD, PhD, Dirk Reinhardt, MD, PhD, Ursula Creutzig, MD, PhD, Gertjan J. Kaspers, MD, PhD

Blood (2011) 118 (21): 4873.

https://doi.org/10.1182/blood.V118.21.4873.4873

Published: 2011

Journal Articles

Characterization of CEBPA Mutations and Promoter Hypermethylation in Pediatric Acute Myeloid Leukemia.

Iris H.I.M. Hollink, MD, Marry M. van den Heuvel-Eibrink, MD, PhD, Susan T.C.J.M. Arentsen-Peters, Martin Zimmermann, PhD, Justine K. Peeters, PhD, Peter J. Valk, PhD, Brian V. Balgobind, MD, Gertjan J.L. Kaspers, MD, PhD, Evelina S.J.M. de Bont, MD, PhD, Siebold S.N. de Graaf, MD, PhD, Jan Trka, PhD, Jan Stary, MD, PhD, Jean-Michel Cayuela, PhD, Andre Baruchel, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD, Rob Pieters, MD, PhD, C. Michel Zwaan, MD, PhD

Blood (2009) 114 (22): 1605.

https://doi.org/10.1182/blood.V114.22.1605.1605

Published: 2009

Journal Articles

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

Annette Sander, MD, Martin Zimmermann, PhD, Dirk Reinhardt, MD, PhD, Michael Dworzak, MD, PhD, Gertjan Kaspers, MD, PhD, Ursula Creutzig, MD, PhD

Blood (2008) 112 (11): 963.

https://doi.org/10.1182/blood.V112.11.963.963

Published: 2008

Journal Articles

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in “Down” Syndrome.

Katarina Reinhardt, PhD, Katarina Boehmer, Jan-Henning Klusmann, MD, Manuela Germeshausen, PhD, Annette Sander, MD, Christine von Neuhoff, MD, Jan Stary, MD, PhD, Heribert Jürgens, MD, PhD, Arnulf Pekrun, MD, PhD, Axel Sauerbrey, MD, PhD, Charlotte M Niemeyer, MD, PhD, Gudrun Fleischhack, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2008) 112 (11): 923.

https://doi.org/10.1182/blood.V112.11.923.923

Published: 2008

Journal Articles

FLT3 and KIT Mutated Pediatric Acute Myeloid Leukemia (AML) Samples Are More Sensitive In Vitro to the Tyrosine Kinase Inhibitor SU11657.

Bianca F. Goemans, MD, Christian M. Zwaan, MD,PhD, Desiree de Lange, Jacqueline Cloos, PhD, Dirk Reinhardt, MD,PhD, Karel Hahlen, MD,PhD, Brenda E.S. Gibson, MD,PhD, Ursula Creutzig, MD,PhD, GertJan J.L. Kaspers, MD,PhD

Blood (2006) 108 (11): 1359.

https://doi.org/10.1182/blood.V108.11.1359.1359

Published: 2006

Journal Articles

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Hendrik J.M. de Jonge, Arja ter Elst, PhD, H. Marike Boezen, PhD, Alida C. Weidenaar, Frank J.G. Scherpen, Jessica C.A. Bouma-ter Steege, PhD, Gertjan J.L. Kaspers, MD/PhD, Bianca F. Goemans, MD, Ursula Creutzig, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S.J.M. de Bont, MD/PhD

Blood (2006) 108 (11): 838.

https://doi.org/10.1182/blood.V108.11.838.838

Published: 2006

Journal Articles

Large Interindividual Differences in In Vitro Calicheamicin Sensitivity May Underly Gemtuzumab Ozogamicin Resistance in Acute Myeloid Leukemia (AML).

Bianca F. Goemans, MD, Gertjan J.L. Kaspers, MD, PhD, Susanne J.H. Vijverberg, BSc, Anne H. Loonen, Ursula Creutzig, MD, PhD, Karel Hahlen, MD, PhD, Dirk Reinhardt, MD, PhD, Brenda E.S. Gibson, MD, PhD, Jacqueline Cloos, PhD, Christian M. Zwaan, MD, PhD

Blood (2005) 106 (11): 107.

https://doi.org/10.1182/blood.V106.11.107.107

Published: 2005

Journal Articles

Chromosome 21 Encoded RUNX1 and ETS-2 Overexpression in Regenerating Hematopoiesis in Children with Down Syndrome - Implications for Leukemiogenesis?.

Dirk Reinhardt, MD, PhD, Kristin Wortmann, Miriam Kolar, Jan H. Klusmann, Ulrike Puhlmann, Jean P. Bourquin, MD, Ursula Creutzig, MD, PhD, Claudia Langebrake, PhD

Blood (2005) 106 (11): 4373.

https://doi.org/10.1182/blood.V106.11.4373.4373

Published: 2005

NARROW

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Treatment‐Related Acute Myeloid Leukemia in Children

The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study

Gemtuzumab in Children with Relapsed and Refractory Acute Myeloid Leukemia Treated on Compassionate-Use Basis: A Report of the AML-BFM Study Group

Successes and Challenges of Pediatric AML: A Report on Survival, Salvage Therapy and Causes of Deaths in the AML-BFM Study Group from 1987 -2012

Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML

Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG)

Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML.

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Transient and Myeloid Leukemia in Children with Down Syndrome Mosaic

Glucocorticoid-Induced Proliferation and Differentiation of Untreated Pediatric AML Cells

Characterization of CEBPA Mutations and Promoter Hypermethylation in Pediatric Acute Myeloid Leukemia.

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in “Down” Syndrome.

FLT3 and KIT Mutated Pediatric Acute Myeloid Leukemia (AML) Samples Are More Sensitive In Vitro to the Tyrosine Kinase Inhibitor SU11657.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Large Interindividual Differences in In Vitro Calicheamicin Sensitivity May Underly Gemtuzumab Ozogamicin Resistance in Acute Myeloid Leukemia (AML).

Chromosome 21 Encoded RUNX1 and ETS-2 Overexpression in Regenerating Hematopoiesis in Children with Down Syndrome - Implications for Leukemiogenesis?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only